| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Truist Securities analyst Srikripa Devarakonda reiterates Terns Pharma (NASDAQ:TERN) with a Buy and raises the price target ...
BMO Capital analyst Etzer Darout maintains Terns Pharma (NASDAQ:TERN) with a Outperform and raises the price target from $15...
Barclays analyst Etzer Darout maintains Terns Pharma (NASDAQ:TERN) with a Overweight and raises the price target from $14 to...
HC Wainwright & Co. analyst Andres Y. Maldonado upgrades Terns Pharma (NASDAQ:TERN) from Neutral to Buy and announces $2...
William Blair analyst Andy Hsieh upgrades Terns Pharma (NASDAQ:TERN) from Market Perform to Outperform.
Terns Pharmaceuticals shares rise after TERN-701 shows a 75% response rate in the CML trial, and William Blair upgrades the sto...